The University of Rochester Medical Center has received a $27 million grant to conduct a six-year study on implantable cardioverter defibrillators (ICDs) and their impact on the health outcomes of heart failure patients. This research has the potential to revolutionize care on a global scale, as URMC considers it one of the largest awards it has received in the past decade.
The study aims to determine if advancements in medical therapy could potentially reduce the need for ICDs in many individuals living with heart failure. Dr. Ilan Goldenberg, director of the Clinical Cardiovascular Research Center and lead investigator of the study, believes that current analysis suggests that a significant portion of patients who receive ICDs may not actually benefit from them in terms of survival. If the study’s findings support Dr. Goldenberg’s hypothesis, it could lead to changes in practice guidelines for managing heart failure.
This study will enroll over 3,000 patients across 115 sites in the United States and Canada. The impact of this research could be groundbreaking in terms of improving care and outcomes for patients with heart failure.
